In Phase A, participants will obtain distinctive doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. More contributors will likely be enrolled within the identified monotherapy dosign regimen. In Section B, members will get oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Section C, https://gwendolynj664xsh4.59bloggers.com/profile